4-Hydroxytamoxifen inhibits K+ currents in mouse ventricular myocytes

European Journal of Pharmacology

Volumn 629, Issue 1-3, 2010, Pages 96-103

  El Gebeily, Gracia ^a,b   Fiset, Céline ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

4 Hydroxytamoxifen; Estrogen receptor; K+ currents; Mouse; Ventricle

Indexed keywords

4 HYDROXYTAMOXIFEN; CALCIUM ION; DACTINOMYCIN; ESTROGEN RECEPTOR; FULVESTRANT;

ADULT ANIMAL; ANIMAL CELL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; ELECTROPHYSIOLOGY; FEMALE; GENETIC TRANSCRIPTION; HEART MUSCLE CELL; HEART VENTRICLE; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REPOLARIZATION; STEADY STATE; VOLTAGE CLAMP;

ANIMALS; DACTINOMYCIN; ELECTRIC CONDUCTIVITY; ESTRADIOL; FEMALE; HEART VENTRICLES; KINETICS; MICE; MUSCLE CELLS; PATCH-CLAMP TECHNIQUES; POTASSIUM; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 74149086723     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.12.006     Document Type: Article

References (30)

1. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. LANCET 1 (1985) 836-840
2. Bergan R.C., Reed E., Myers C.E., Headlee D., Brawley O., Cho H.K., Figg W.D., Tompkins A., Linehan W.M., Kohler D., Steinberg S.M., and Blagosklonny M.V. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 5 (1999) 2366-2373
3. Best L. Inhibition of glucose-induced electrical activity by 4-hydroxytamoxifen in rat pancreatic beta-cells. Cell. Signal. 14 (2002) 69-73
4. + currents in adult mouse ventricular myocytes. J. Physiol. 559 (2004) 777-798
5. Coezy E., Borgna J.L., and Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42 (1982) 317-323
6. Diaz M. Triphenylethylene antiestrogen-induced acute relaxation of mouse duodenal muscle. Possible involvement of Ca2+ channels. Eur. J. Pharmacol. 445 (2002) 257-266
7. Dick G.M., and Sanders K.M. (Xeno)estrogen sensitivity of smooth muscle BK channels conferred by the regulatory beta1 subunit: a study of beta1 knockout mice. J. Biol. Chem. 276 (2001) 44835-44840
8. Dick G.M., Rossow C.F., Smirnov S., Horowitz B., and Sanders K.M. Tamoxifen activates smooth muscle BK channels through the regulatory beta 1 subunit. J. Biol. Chem. 276 (2001) 34594-34599
9. + current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J. Physiol. 504 (1997) 557-563
10. Furr B.J., and Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25 (1984) 127-205
11. He J., Kargacin M.E., Kargacin G.J., and Ward C.A. Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H661-H668
12. Isenberg G., and Klockner U. Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium". Pflug. Arch. 395 (1982) 6-18
13. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., Desta Z., Flockhart D.A., and Skaar T.C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85 (2004) 151-159
14. Jordan V.C. Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. J Natl. Cancer Inst. 84 (1992) 231-234
15. Kargacin M.E., Ali Z., Ward C.A., Pollock N.S., and Kargacin G.J. Tamoxifen inhibits Ca2+ uptake by the cardiac sarcoplasmic reticulum. Pflug. Arch. 440 (2000) 573-579
16. Katzenellenbogen B.S., Norman M.J., Eckert R.L., Peltz S.W., and Mangel W.F. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res. 44 (1984) 112-119
17. Lien E.A., Solheim E., and Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51 (1991) 4837-4844
18. Lim Y.C., Desta Z., Flockhart D.A., and Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 55 (2005) 471-478
19. Liu X.K., Katchman A., Ebert S.N., and Woosley R.L. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J. Pharmacol. Exp. Ther. 287 (1998) 877-883
20. MacCallum J., Cummings J., Dixon J.M., and Miller W.R. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J. Chromatogr. B Biomed. Appl. 678 (1996) 317-323
21. MacCallum J., Cummings J., Dixon J.M., and Miller W.R. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues. J. Chromatogr. B Biomed. Sci. Appl. 698 (1997) 269-275
22. Monaghan A.S., Mintenig G.M., and Sepulveda F.V. Outwardly rectifying Cl- channel in guinea pig small intestinal villus enterocytes: effect of inhibitors. Am. J. Physiol. Gastrointest. Liver Physiol. 273 (1997) G1141-G1152
23. Park W.C., and Jordan V.C. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol. Med. 8 (2002) 82-88
24. Pollack I.F., DaRosso R.C., Robertson P.L., Jakacki R.L., Mirro Jr. J.R., Blatt J., Nicholson S., Packer R.J., Allen J.C., Cisneros A., and Jordan V.C. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin. Cancer Res. 3 (1997) 1109-1115
25. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. LANCET 2 (1987) 171-175
26. Ruenitz P.C., Bagley J.R., and Mokler C.M. Estrogen receptor binding and estrogenic/antiestrogenic effects of two new metabolites of nitromiphene, 2-[p-[2-nitro-1-(4-methoxyphenyl)-2-phenylvinyl]phenoxy]-N-ethylpyrrolidine. J. Med. Chem. 26 (1983) 1701-1705
27. Trépanier-Boulay V., St-Michel C., Tremblay A., and Fiset C. Gender-based differences in cardiac repolarization in mouse ventricle. Circ. Res. 89 (2001) 437-444
28. Trump D.L., Smith D.C., Ellis P.G., Rogers M.P., Schold S.C., Winer E.P., Panella T.J., Jordan V.C., and Fine R.L. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 84 (1992) 1811-1816
29. Winer E.P., Hudis C., Burstein H.J., Chlebowski R.T., Ingle J.N., Edge S.B., Mamounas E.P., Gralow J., Goldstein L.J., Pritchard K.I., Braun S., Cobleigh M.A., Langer A.S., Perotti J., Powles T.J., Whelan T.J., and Browman G.P. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol. 20 (2002) 3317-3327
30. Zhang J.J., Jacob T.J., Valverde M.A., Hardy S.P., Mintenig G.M., Sepulveda F.V., Gill D.R., Hyde S.C., Trezise A.E., and Higgins C.F. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J. Clin. Invest. 94 (1994) 1690-1697